Companies · Biotechnology

Cesca Therapeutics Inc.

RANCHO CORDOVA · Biotechnology

Diligence memoA one-page analyst read on Cesca Therapeutics Inc. — recommendation, valuation, rhythm, risks.
$34.6M
Total raised · real
5
Rounds
3.8×
Latest step-up
Top 24%
Sector rank · raised
Series A
Latest stage · inferred · Mon Mar 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Cesca Therapeutics Inc. looks under-valued against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.66× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era.
At-risk
  • Last raise 3.3 yr ago; this sector typically re-raises about every 14 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Cesca Therapeutics Inc. is one of 4291 Biotechnology companies tracked from RANCHO CORDOVA. By capital raised it ranks in the upper tier (ahead of 77% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

pharma

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
1
Investors (latest)
2023-03-20
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeries A · 2014-08-31 Raised $15M (real) Modeled valuation $542M (est)$15M$542MSeries A2014Series A · 2016-02-13 Raised $15M (real) Modeled valuation $542M (est)$15M$542MSeries A2016Series A · 2018-03-26 Raised $817K (real) Modeled valuation $30M (est)$817K$30MSeries A2018Series A · 2019-01-29 Raised $800K (real) Modeled valuation $29M (est)$800K$29MSeries A2019Series A · 2023-03-20 Raised $3.0M (real) Modeled valuation $29M (est)$3.0M$29MSeries A2023+$15M+$817K+$800K+$3.0MCumulative $35M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$15.0M · 2014
Series A extension$15.0M · 2016
Series A extension$817K · 2018
Series A extension$800K · 2019
Series A extension$3.0M · 2023

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$29.2M
Base estimate est.
$3.3M
Conservative case
$85.0M
Upside case
$13.6M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $542.3M · 2014-08-312014Series A · modeled $542.3M · 2016-02-13Series A · modeled $29.5M · 2018-03-26Series A · modeled $28.9M · 2019-01-29Series A · modeled $29.2M · 2023-03-202023
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
3.3 yr
Elapsed time used
3.3 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
26 mo
Avg between rounds
$4.0M/yr
Capital velocity
11.8 yr
On record since
2014
First round
5
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 4.8× above median
This company$34.6M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.6× of median
This company$3.0M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 0.5× of median
This company$29.2M
Sector median$64.2M

Raised more than 77% of sector peers (real $). Modeled value above 35% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #200 of 303.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0M$100.0MCapital raised (log)GeoVax Labs, Inc. · Series A Raised $39.1M · modeled $217.0M (est)Cellinfinity Bio Holding Company, LLC · Series A Raised $13.2M · modeled $215.9M (est)Adient Medical, Inc. · Series A Raised $18.2M · modeled $206.8M (est)Entegrion Inc · Series A Raised $22.7M · modeled $191.3M (est)BCD Bioscience, Inc. · Series A Raised $16.4M · modeled $188.9M (est)Pragma Biosciences Inc. · Series A Raised $14.5M · modeled $186.0M (est)MicroByre, Inc. · Series A Raised $16.1M · modeled $185.7M (est)Cardiac Insight, Inc. · Series A Raised $38.1M · modeled $183.8M (est)Cardiac Implants LLC · Series A Raised $13.5M · modeled $178.2M (est)Abintus Bio, Inc. · Series A Raised $13.7M · modeled $177.2M (est)Mosaic Biosciences, Inc. · Series A Raised $14.7M · modeled $176.1M (est)Mazen Animal Health Inc. · Series A Raised $13.5M · modeled $168.8M (est)Cesca Therapeutics Inc. (this company) Raised $34.6M · modeled $29.2M (est)Cesca Therapeutics Inc.
CompanyStageRaised · realValue · estvs peer med.
GeoVax Labs, Inc.Series A$39.1M$217.0M4.90×
Cellinfinity Bio Holding Company, LLCSeries A$13.2M$215.9M4.87×
Adient Medical, Inc.Series A$18.2M$206.8M4.67×
Entegrion IncSeries A$22.7M$191.3M4.32×
BCD Bioscience, Inc.Series A$16.4M$188.9M4.27×
Pragma Biosciences Inc.Series A$14.5M$186.0M4.20×
MicroByre, Inc.Series A$16.1M$185.7M4.19×
Cardiac Insight, Inc.Series A$38.1M$183.8M4.15×
Cardiac Implants LLCSeries A$13.5M$178.2M4.02×
Abintus Bio, Inc.Series A$13.7M$177.2M4.00×
Mosaic Biosciences, Inc.Series A$14.7M$176.1M3.98×
Mazen Animal Health Inc.Series A$13.5M$168.8M3.81×
Cesca Therapeutics Inc. this companySeries A$34.6M$29.2M0.66×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$15.0M2014-08-31$68.2M$542.3M85%
Series A$15.0M2016-02-13$68.2M$542.3M85%
Series A$817K2018-03-26$3.7M$29.5M90%
Series A$800K2019-01-29$3.6M$28.9M90%
Series A$3.0M2023-03-20$13.6M$29.2M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$15.0M2014-08-31
    • First recorded raise — entered as Series A.
    • 2 investors on this round.
  2. Series A$15.0M2016-02-13
    • Raised 17 mo later, in step with the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 2 investors on this round.
  3. Series A$817K2018-03-26
    • Raised again after 25 mo — slower than the ~14 mo sector norm.
    • Round 18.4× smaller than the prior — bridge or down round.
    • 5 investors on this round.
  4. Series A$800K2019-01-29
    • Raised 10 mo later, in step with the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
  5. Series A$3.0M2023-03-20
    • Raised again after 50 mo — slower than the ~14 mo sector norm.
    • Round 3.8× larger than the prior — scaling up.
    • 1 investor on this round.
Intelligence
2025 ~Q2
Modeled next raise · ~26mo cadence
$9.0M
Modeled next size est.range $5.9M$14.4M
3.8×
Last step-up
$4.0M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Haihong Zhu1 other2023-03
Mark Westgate1 other2018-03
Vivian Liu1 other2018-03
Craig W Moore2014-08
Denis Michael Rhein2016-02
James Xu2018-03
Jeff Cauble2018-03
Jeffery Cauble2019-01
Joseph Thomis2018-03
Kenneth C Pappa2014-08
Kenneth W Harris2014-08
Mahendra S. Rao2016-02
Mahendra W Rao2014-08
Michael Bruch2016-02
Michael C Rhein2014-08
Mike C Bruch2014-08
Mitchel C Sivilotti2014-08
Robin C Stacey2014-08
Robin Stracey2016-02
Russell Medford2018-03
Xiaochun Xu2018-03
Registry & provenance

Cesca Therapeutics Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
811212
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Seelos Therapeutics, Inc.BiotechnologySeries A$27.7M$5.9Mnetwork1 shared operator · same sector · same stage
Carterra, Inc.BiotechnologySeries A$34.5M$34.5Msame sector · same stage
Relmada Therapeutics, Inc.BiotechnologySeries A$36.1M$29.9Msame sector · same stage
Solarea Bio, Inc.BiotechnologySeries A$37.2M$27.2Msame sector · same stage
MedShape Solutions, Inc.BiotechnologySeries A$31.4M$25.3Msame sector · same stage
Nacuity Pharmaceuticals, Inc.BiotechnologySeries A$31.2M$21.9Msame sector · same stage
Stagezero Life Sciences Ltd.BiotechnologySeries A$27.1M$23.9Msame sector · same stage
Mabvax Therapeutics Holdings, Inc.BiotechnologySeries A$25.0M$30.0Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Tasca Therapeutics CorpBiotechnologySeries C$372.3M90%
Cedilla Therapeutics, Inc.BiotechnologySeries C$3.1B89%
Cerium Pharmaceuticals, Inc.BiotechnologySeries A$193.1M86%
Ceptur Therapeutics, Inc.BiotechnologySeries B$452.7M86%
Cessation Therapeutics, Inc.BiotechnologySeries A$5.9M85%
Eikon Therapeutics, Inc.BiotechnologyGrowth/Late$3.8B85%
Lirum Therapeutics, Inc.BiotechnologySeries A$64.7M84%
CeleCor Therapeutics, Inc.BiotechnologySeries C$993.8M84%
Frequently asked
How much funding has Cesca Therapeutics Inc. raised?
Cesca Therapeutics Inc. has raised approximately $34.6M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is Cesca Therapeutics Inc.'s estimated valuation?
Provath's modeled valuation for Cesca Therapeutics Inc. is approximately $29.2M (modeled range $3.3M–$85.0M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Cesca Therapeutics Inc. at?
Cesca Therapeutics Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Mon Mar 20.
What does Cesca Therapeutics Inc. do and where is it based?
Cesca Therapeutics Inc. operates in the Biotechnology sector, based in RANCHO CORDOVA.
Explore related

See where Cesca Therapeutics Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Cesca Therapeutics Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.